IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.

出版年份 2018 全文链接

标题

作者

关键词

出版物

Volume 36, Issue 15_suppl, Pages TPS4141-TPS4141

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2018-09-05

DOI

10.1200/jco.2018.36.15_suppl.tps4141

Explore over 38,000 international journals covering a vast array of academic fields.

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now